Alcohol-associated hepatitis
Severe alcohol-associated (alcoholic) hepatitis carries up to ~30-50% short-term mortality, and corticosteroids are the only marginally effective drug therapy, so there is an urgent need for alternatives. A landmark mechanism links the gut bacterium Enterococcus faecalis to disease severity: cytolysin-positive ("cytolytic") strains secrete a two-subunit exotoxin that translocates to the liver, kills hepatocytes, and worsens injury, and fecal cytolysin positivity correlates with mortality. Because cytolysin is produced by a defined bacterial subset rather than the whole microbiome, phages are exceptionally well suited here — they can strip out the toxin-producing strains with surgical precision while sparing the rest of the gut flora, something broad-spectrum antibiotics cannot do (and antibiotics risk fueling resistant enterococci). This makes cytolytic E. faecalis one of the cleanest "precision phage" targets in hepatology.
How phages act here
Mechanism
The therapeutic strategy uses lytic phages isolated from sewage that specifically infect and lyse cytolysin-positive E. faecalis. Because individual phages have narrow host ranges, a cocktail (a 3-phage mix derived from a panel of ~20 isolates, with ~6 broad-host-range phages) is used to cover most clinically relevant cytolytic strains and to suppress resistance. Mechanistically, oral phages reduce intestinal cytolytic E. faecalis burden, which lowers translocation of cytolysin to the liver and attenuates ethanol-induced steatosis, hepatocyte death, and inflammation; the phages themselves also translocate to serum, spleen and liver, where the immune response observed was predominantly anti-inflammatory and tissue-restoring rather than harmful. A notable resistance angle: phage-resistant variants arise via IS256 insertion-sequence events (disrupting xylA and deleting surface-polysaccharide genes such as galE/epaR), but these escape mutants pay a steep fitness cost — reduced intestinal adherence and increased bile-salt sensitivity — so resistance tends to coincide with impaired gut colonization rather than treatment failure. Synthetic-genomics/engineered-phage approaches have been floated to broaden coverage to all cytolysin-positive strains.
Where it stands
Current evidence
Evidence is robust but still preclinical for this specific indication — there is no completed human efficacy trial of cytolytic E. faecalis phage cocktails in alcohol-associated hepatitis as of 2026. The foundational proof of concept is Duan et al., Nature 2019, which used humanized (fecal-transplanted) mice and showed phage targeting of cytolytic E. faecalis abolished ethanol-induced liver disease; the work was a J. Craig Venter Institute (Derrick Fouts) and UC San Diego (Bernd Schnabl) collaboration with a large international consortium (Columbia, Yale, King's College London, and centers in Spain, France, Belgium, Canada). A follow-up (Garcia Mendes et al., Viruses 2022) characterized a clinical-grade 3-phage oral cocktail, found it safe with an anti-inflammatory immune profile, and explicitly framed it as ready for clinical-trial consideration. A 2025 mechanistic paper (Fujiki et al., Microbiology Spectrum) clarified how phage resistance emerges and why it carries a colonization fitness cost. Importantly for calibration, a 2025 prospective Danish cohort reported LOW incidence of cytolysin-positive E. faecalis and NO correlation with survival in their alcohol-associated hepatitis patients, suggesting the cytolysin-mortality link (and thus the addressable patient population) may be cohort/geography-dependent. Investigators continue to cite additional safety testing and synthetic-genomics scale-up as prerequisites before first-in-human trials.
Evidence confidence: medium
The data
Key studies & trials
- Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. (incl. Fouts DE, Schnabl B). Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505-511. ↗
- Garcia Mendes B, Duan Y, Schnabl B. Immune Response of an Oral Enterococcus faecalis Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease. Viruses. 2022;14(3):490. ↗
- Fujiki J, Nakamura T, Kreimeyer H, Llorente C, Fouts DE, Schnabl B. Insertion sequence-mediated phage resistance contributes to attenuated colonization of cytolytic Enterococcus faecalis variants in the gut. Microbiology Spectrum. 2025; doi:10.1128/spectrum.03303-24 (PMID: 40231830). ↗
- Duan Y, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (full text). Nature. 2019;575(7783):505-511. DOI: 10.1038/s41586-019-1742-x. ↗
Who is working on it
Programs & centers
The possibility
If first-in-human trials confirm the mouse data, an oral phage cocktail could become the first precision microbiome drug for severe alcohol-associated hepatitis — a simple, swallowed therapy that disarms a liver-killing toxin at its bacterial source while leaving the rest of the gut intact, potentially given alongside or instead of steroids. Paired with a rapid stool qPCR companion test for cytolysin, clinicians could screen patients in the ICU and treat only the cytolysin-positive subset most likely to benefit, a true theranostic. Engineered and synthetic-genomics phages designed to cover every cytolytic strain — and to exploit the fitness cost of resistance — could ultimately turn one of hepatology's deadliest emergencies into a targetable, drug-treatable condition.